Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A

Note: Funding Information: R. Schutgens has received research grants from Bayer, Shire, CSL Behring, NovoNordisk, Pfizer, Sanquin and Sobi. P.R. van der Valk received a research grant from Shire. L.F.D. van Vulpen has received a research grant funding award from NovoNordisk. E.P. Mauser-Bunschoten received research grants/educational support from CSL Behring, Bayer, Baxter, Griffols, Novo Nordisk, Pfizer, Biotest, Shire and Sanquin. K. Fischer has received speaker’ s fees from Bayer, Baxter, Biotest, CSL Behring, Biotest Octapharma, Pfizer and NovoNordisk; performed consultancy for Bayer, Baxter, Biogen, CSL-Behring, Freeline, NovoNordisk, Pfizer and SOBI; and has received research grants from Bayer, Pfizer, Baxter and Novo Nordisk. None of the above mentioned organisations were involved in preparing this manuscript, in the individual treatment protocol or in writing or reviewing this manuscript. RG, EM, KF, PV and IK developed the local guidelines determining the target levels for central venous catheter placement in different age groups. RG, EM, KF, PV and IK developed the individual factor replacement protocol in this case, adjusted the continuous infusion rate according to FVIII levels and clinical status during surgery and during the post-operative period. RG, PV, LV, EM, KF and IK interpreted the clinical and laboratory data. IK and KF prepared the manuscript, specifically writing the initial draft. RG, PV, LV and EM prepared the manuscript, specifically by critical review and commentary. Funding Information: R. Schutgens has received research grants from Bayer, Shire, CSL Behring, NovoNordisk, Pfizer, Sanquin and Sobi. P.R. van der Valk received a research grant from Shire. L.F.D. van Vulpen has received a research grant funding award from NovoNordisk. E.P. Mauser-Bunschoten received research grants/educational support from CSL Behring, Bayer, Baxter, Griffols, Novo Nordisk, Pfizer, Biotest, Shire and Sanquin. K. Fischer has received speaker's fees from Bayer, Baxter, Biotest, CSL Behring, Biotest Octapharma, Pfizer and NovoNordisk; performed consultancy for Bayer, Baxter, Biogen, CSL-Behring, Freeline, NovoNordisk, Pfizer and SOBI; and has received research grants from Bayer, Pfizer, Baxter and Novo Nordisk. None of the above mentioned organisations were involved in preparing this manuscript, in the individual treatment protocol or in writing or reviewing this manuscript. RG, EM, KF, PV and IK developed the local guidelines determining the target levels for central venous catheter placement in different age groups. RG, EM, KF, PV and IK developed the individual factor replacement protocol in this case, adjusted the continuous infusion rate according to FVIII levels and clinical status during surgery and during the post-operative period. RG, PV, LV, EM, KF and IK interpreted the clinical and laboratory data. IK and KF prepared the manuscript, specifically writing the initial draft. RG, PV, LV and EM prepared the manuscript, specifically by critical review and commentary.